ORCA BIO ANNOUNCES FDA REVIEW EXTENSION OF BLA FOR ORCA-T FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
ORCA BIO: NEW PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS JULY 6, 2026
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.